Trademark Overview
On Monday, August 21, 2023, a trademark application was filed for BIOCOLONIZE with the United States Patent and Trademark Office. The USPTO has given the BIOCOLONIZE trademark a serial number of 98143029. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Wednesday, July 24, 2024. This trademark is owned by Melius Microbiomics Inc.. The BIOCOLONIZE trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for human use in the field of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of mental health disorders
Medical, scientific and veterinary research, namely clinical trials; conducting interventional clinical studies; pharmaceutical drug development services for others; pharmaceutical product evaluation; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific research information in the fields of pharmaceuticals; medical, scientific and veterinary research in the fields of clinical trials and post-market trials; research on the subject of pharmaceuticals; scientific research for the development of CRISPR-based platforms and products in the field of genetic engineering